Hypercholesterinämie: Monoklonale Antikörper sicher und effektiv

Monoklonale Antikörper, die das Proprotein Convertase Subtilisin / Kexin Typ 9 (PCSK9) hemmen, senken signifkant das LDL-Cholesterin. Das haben erste Studien mit kurzer Laufzeit bereits gezeigt. Umfassendere Studien belegen nun die Wirksamkeit und Sicherheit von monoklonalen PCSK9-Antikörpern in Kombination mit Statinen.

• Literatur

• 1 Koren MJ et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol 2014; 63: 2531-2540
• 2 Stroes E et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014; 63: 2541-1548
• 3 Moriarty PM et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol 2014; 8: 554-561
• 4 Moriarty PM Präsentation, AHA Chicago, November 2014. Im Internet: www.my.americanheart.org Stand: 13.04.2015
• 5 Poirier S et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem 2008; 283: 2363-2372
• 6 Awan Z et al. Regional distribution and metabolic effect of PCSK9 insLEU and R46L gene mutations and apoE genotype. Can J Cardiol 2013; 29: 927-933
• 7 Seidah NG et al. PCSK9: a key modulator of cardiovascular health. Circ Res 2014; 114: 1022-1036
• 8 Zhao Z et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006; 79: 514-523